· Alteogen is developing a long-acting active form of coagulation factor VII (FVIIa), which employs our proprietary NexP™ technology for treating hemophilia. ALT-Q2 (FVIIa-NexP™) is a recombinant fusion protein of FVIIa and NexP™.
· Hemophilia is a bleeding disorder with a delayed clotting process. FVIIa is a bypass agent for treating hemophilia patients with inhibitory antibody against coagulation factor VIII or IX. Currently, NovoSeven (Novo Nordisk) dominates the FVIIa market. However, the half-life of NovoSeven drug is short (~ 2 h). Short half-life of the drug causes for patients to intake multiple doses before reaching hemostasis. ALT-Q2 has shown much longer half-life and better in vivo efficacy in animal studies among hemophilia mice. Pre-clinical GLP toxicology studies will be underway to prove its safety and efficacy.